Floatz logo

Valganciclovir

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)Small moleculePhase 3Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
81/ 100

Competitive context

62 Active assets in the HIV Infections cohort.

Asset / SponsorPhaseRating
Raltegravir
Helsinki University Central Hospital
Phase 4A
ZIDOVUDINE
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase 4BBB
Efavirenz
The Cleveland Clinic
Phase 4BBB
Abacavir
Germans Trias i Pujol Hospital
Phase 4BBB
NEVIRAPINE ANHYDROUS
Germans Trias i Pujol Hospital
Phase 4BBB

View all 50 →

Same molecule, other indications

Valganciclovir is also rated in:

cytomegalovirus infectionDormant
BB
Indicative ·
68 / 100
View asset →
lymphoproliferative syndromeDormant
B
Indicative ·
61 / 100
View asset →
Epstein-Barr virus-associated lymphoproliferative disorderDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →